Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in the Netherlands: Insights From CHOICE-CSU 2 Study
Author(s)
Kirsten Gertsen, MSc1, Aad Wissink, MSc2, panagiotis Orfanos, II, MSc3, Cristina Constantinescu, MSc4, Ravneet Kaur Kohli, Master of Pharmacy5.
1Novartis Pharma BV, Amsterdam, Netherlands, 2Novartis Pharma B.V., Amsterdam, Netherlands, 3Novartis Pharma AG, Basel, Switzerland, 4Ipsos, Basel, Switzerland, 5Novartis Healthcare Pvt. Ltd., Bengaluru, India.
1Novartis Pharma BV, Amsterdam, Netherlands, 2Novartis Pharma B.V., Amsterdam, Netherlands, 3Novartis Pharma AG, Basel, Switzerland, 4Ipsos, Basel, Switzerland, 5Novartis Healthcare Pvt. Ltd., Bengaluru, India.
OBJECTIVES: Chronic spontaneous urticaria (CSU) is characterized by unpredictable itch, and hives with or without angioedema lasting over six weeks without external triggers. With the development of novel therapies, understanding patient preferences for treatment attributes, such as efficacy, safety, and mode of administration, is critical. The CHOICE-CSU 2 study evaluated treatment preferences among adult patients with CSU inadequately controlled by H1- antihistamines in the Netherlands.
METHODS: A quantitative online survey was conducted among adult patients with CSU in the Netherlands, who were inadequately controlled by H1-antihistamines (Urticaria Control Test 7 [UCT] < 12). Participants were recruited via patient panels, advocacy groups, social media, and specialist referrals. The relative importance of treatment attributes and preference between hypothetical treatment profiles were identified using a Maximum Different Scaling Exercise and a Discrete Choice Experiment. Key attributes assessed included urticaria control, speed of onset of treatment effect, impact on quality of life (QoL), sleep improvement, swelling reduction, mode of administration, side effects, and injection site reactions. Sensitivity analysis with scenarios of parity in efficacy were conducted to assess robustness of the results.
RESULTS: The interim analysis included 30 patients with CSU (90% women, median age 50 years). Of participants, more than 70% experienced angioedema, on average twice a month. Based on patient preferences, the top five prioritized attributes were well-controlled urticaria, fast onset of treatment effect, the impact of urticaria on QoL, side effects, and effect on swelling. When attributes were evaluated using comparable efficacy, two thirds of patients preferred oral treatment over injectable. Scenarios assuming parity in efficacy consistently indicated a stronger preference for oral treatments.
CONCLUSIONS: Patients prefer oral CSU treatments over injectables when efficacy and safety are comparable. The most important attributes patients consider when choosing a therapy are well-controlled urticaria and fast onset of treatment effect.
METHODS: A quantitative online survey was conducted among adult patients with CSU in the Netherlands, who were inadequately controlled by H1-antihistamines (Urticaria Control Test 7 [UCT] < 12). Participants were recruited via patient panels, advocacy groups, social media, and specialist referrals. The relative importance of treatment attributes and preference between hypothetical treatment profiles were identified using a Maximum Different Scaling Exercise and a Discrete Choice Experiment. Key attributes assessed included urticaria control, speed of onset of treatment effect, impact on quality of life (QoL), sleep improvement, swelling reduction, mode of administration, side effects, and injection site reactions. Sensitivity analysis with scenarios of parity in efficacy were conducted to assess robustness of the results.
RESULTS: The interim analysis included 30 patients with CSU (90% women, median age 50 years). Of participants, more than 70% experienced angioedema, on average twice a month. Based on patient preferences, the top five prioritized attributes were well-controlled urticaria, fast onset of treatment effect, the impact of urticaria on QoL, side effects, and effect on swelling. When attributes were evaluated using comparable efficacy, two thirds of patients preferred oral treatment over injectable. Scenarios assuming parity in efficacy consistently indicated a stronger preference for oral treatments.
CONCLUSIONS: Patients prefer oral CSU treatments over injectables when efficacy and safety are comparable. The most important attributes patients consider when choosing a therapy are well-controlled urticaria and fast onset of treatment effect.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR251
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Sensory System Disorders (Ear, Eye, Dental, Skin)